Review Article

Neuroprotection and Neurodegeneration in Alzheimer’s Disease: Role of Cardiovascular Disease Risk Factors, Implications for Dementia Rates, and Prevention with Aerobic Exercise in African Americans

Thomas O. Obisesan,1 Richard F. Gillum,1 Stephanie Johnson,1 Nisser Umar,1 Deborah Williams,2 Vernon Bond,3 and John Kwagyan4

1 Division of Geriatrics, Department of Medicine, Howard University Hospital, 2041 Georgia Avenue, NW, Washington, DC 20059, USA
2 Division of Cardiology, Department of Medicine, Howard University Hospital, 2041 Georgia Avenue, NW, Washington, DC 20059, USA
3 Department of Health and Human Performance, Howard University Hospital, 2041 Georgia Avenue, NW, Washington, DC 20059, USA
4 Howard University Hospital, Georgetown–Howard Universities Center for Clinical and Translational Science, 2041 Georgia Avenue, NW, Washington, DC 20059, USA

Correspondence should be addressed to Thomas O. Obisesan, tobisesan@howard.edu

Received 5 December 2011; Revised 9 February 2012; Accepted 12 February 2012

Copyright © 2012 Thomas O. Obisesan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Prevalence of Alzheimer’s disease (AD) will reach epidemic proportions in the United States and worldwide in the coming decades, and with substantially higher rates in African Americans (AAs) than in Whites. Older age, family history, low levels of education, and ε4 allele of the apolipoprotein E (APOE) gene are recognized risk factors for the neurodegeneration in AD and related disorders. In AAs, the contributions of APOE gene to AD risk continue to engender a considerable debate. In addition to the established role of cardiovascular disease (CVD) risk in vascular dementia, it is now believed that CVD risk and its endophenotype may directly mediate AD phenotype. Given the pleiotropic effects of APOE on CVD and AD risks, the higher rates of CVD risks in AAs than in Whites, it is likely that CVD risks contribute to the disproportionately higher rates of AD in AAs. Though the advantageous effects of aerobic exercise on cognition is increasingly recognized, this evidence is hardly definitive, and data on AAs is lacking. In this paper, we will discuss the roles of CVD risk factors in the development of AD and related dementias, the susceptibility of these risk factors to physiologic adaptation, and fitness-related improvements in cognitive function. Its relevance to AD prevention in AAs is emphasized.

1. Introduction

Although anticholinesterase therapies have greatly improved symptomatic treatment of AD, they have not been demonstrated to significantly slow disease progression. Excess morbidity and mortality from AD continue to generate enormous economic burden on families and on the United States. Preservation of intellectual dexterity among those showing earliest symptoms of AD may ameliorate the physical, emotional, and economic burden associated with the disease, and that is an important public health goal.

A promising evidence-based and relatively side-effect free lifestyle approach is emerging as an alternative or adjunct to anticholinesterase therapy. Specifically, aerobic exercise training has been demonstrated to improve cognitive function (Figure 1). Though, the effect sizes for these studies were surprisingly large, and the results fairly consistent, however, the sample sizes were small and included mostly
Figure 1: Aerobic exercise training and cognitive functions. Aerobic exercise increases HDL-C and subfractions; decrease total cholesterol, C-reactive protein, and interleukin-1; improves endothelia function and arterial compliance; improves glucose homeostasis and downregulates hypoxia.

Whites. Importantly, the mechanism by which an advantageous effect occurs is yet to be systematically examined. Remarkably, aerobic fitness can improve many of the putative AD risk factors such as high-density lipoprotein cholesterol (HDL-C), inflammation, and arteriolosclerosis. However, improvements in these risk factors have not been optimally explored as potential mechanisms by which aerobic training improves cognitive function in humans and AA in particular. Given that AAs (i) have higher incidence and prevalence of AD than Whites, (ii) have paucity of cross-sectional and lack prospective data on the beneficial effect of exercise on cognitive function and (iii) are more sedentary relative to Whites, in whom data show the beneficial effect of exercise, and therefore have more room for exercise-induced improvements in risk, it is relevant that the beneficial effects of aerobic fitness on neurocognitive processes is prospectively examined in this population.

2. Magnitude of Alzheimer’s Disease Burden

Clinically, AD is a constellation of gradual decline in memory, other cognitive functions, behaviors, and activities of daily living leading to total dependency [1]. Pathologically, AD is a heterogeneous neurodegenerative disorder characterized by amyloid-beta plaques (Aβ), neurofibrillary tangles, inflammation, and neuronal loss. AD is the most common type of dementia constituting ~2/3rd of all late-life dementias and is estimated to affect 8 percent of persons age 65 years or older [2]. The prevalence of AD increased about 15-fold from 3 percent among individuals between the ages of 65, and 74 years to 47 percent for persons age 85 and older [3]. Also, the incidence of AD increased from 0.5 percent per year at age 65, to ~8 percent per year over age 85 [4, 5]. Without AD, hypertension, and other chronic age-related medical conditions, many older persons would remain relatively functional until late in life, contributing to society. That would reduce the nation’s dependency ratio [6]. Based on 1999 estimates, the annual health care cost for AD was ~$100 billion [7]. Excluding ~$202 billion in uncompensated care by ~15 million families and caregivers, total payments in 2011 for health care, long-term care, and hospice services for people aged ≥65 years with AD and other dementias were estimated to be $183 billion [8]. Given this staggering cost and the projected increase in elderly population by the year 2050, identifying effective mechanisms to ward off structural and functional declines of AD is an important public health goal.

3. AD in African Americans

The incidence and prevalence of AD is higher in AAs than Blacks from Sub-Sahara African and compared to persons of European descent. In spite of this statistics, the disease is understudied in AAs [9]. In the Multi-Institutional Research on Alzheimer’s Disease Genetic Epidemiology (MIRAGE) study led by Farrer et al., the adjusted cumulative risk of
Table 1: Number of deaths, population, and rate of death per 100,000 with underlying or contributing cause coded as dementia by division and race in persons aged 65 and over: United States 1999–2004.

| Division          | Race                          | Death 65y+ | Population 65y+ | Crude rate 65y+ | Age adjusted rate 65y+ |
|-------------------|-------------------------------|------------|-----------------|-----------------|------------------------|
| New England       | Black or African American     | 1,683      | 340,854         | 494             | 574                    |
|                   | White                         | 77,719     | 10,875,302      | 715             | 633                    |
| Middle Atlantic   | Black or African American     | 10,145     | 3,119,034       | 325             | 362                    |
|                   | White                         | 155,700    | 28,965,773      | 538             | 492                    |
| East North Central| Black or African American     | 17,106     | 2,836,888       | 603             | 671                    |
|                   | White                         | 219,113    | 31,040,245      | 706             | 664                    |
| West North Central| Black or African American     | 3,476      | 493,880         | 704             | 757                    |
|                   | White                         | 115,938    | 14,864,882      | 780             | 687                    |
| South Atlantic    | Black or African American     | 37,538     | 5,553,447       | 676             | 731                    |
|                   | White                         | 240,812    | 36,129,123      | 667             | 676                    |
| East South Central| Black or African American     | 11,422     | 1,798,196       | 635             | 625                    |
|                   | White                         | 75,592     | 11,093,302      | 681             | 721                    |
| West South Central| Black or African American     | 12,364     | 2,158,225       | 573             | 597                    |
|                   | White                         | 118,490    | 18,293,681      | 648             | 676                    |
| Mountain          | Black or African American     | 1,242      | 232,688         | 534             | 688                    |
|                   | White                         | 78,387     | 12,005,553      | 653             | 687                    |
| Pacific           | Black or African American     | 8,352      | 1,283,968       | 650             | 725                    |
|                   | White                         | 181,815    | 25,078,447      | 725             | 683                    |

### US total

| Race                          | Death 65y+ | Population 65y+ | Crude rate 65y+ | Age adjusted rate 65y+ |
|-------------------------------|------------|-----------------|-----------------|------------------------|
| Black or African American     | 103,328    | 17,799,544      | 581             | 628                    |
| White                         | 1,263,566  | 188,249,878     | 671             | 647                    |

Dementia in the first degree relatives of probands with AD in AAs was approximately twice that of a similar White sample. According to reports from the Indianapolis-Ibadan Dementia Project, the rates of AD and dementia in Yoruba (an ancestral population in Nigeria) are less than half the rates in AAs [10], suggesting possible contributions from the environment.

To better discern the relatively high rates of AD in AAs, a number of studies have compared the prevalence and incidence of AD and related disorders across populations in the US. Whereas a faster rate of cognitive decline in Mild Cognitively Impaired (MCI) AAs than in non-AA was observed in one study that used a community-based sample [11], others found no evidence of racial disparities in cognitive trajectories of MCI [12, 13]. However, in AAs compared to Whites, a significantly slower rate of cognitive decline was reported once AD begins [13, 14]. For example, using age and education adjusted growth curve approach to estimate individual paths of change in global cognition, Barnes reported that older AAs had a lower level of global cognition at baseline and declined at ~25% slower rate compared to Whites [14]. In another study that examined the severity of AD at the time of presentation to the medical establishment among different ethnic groups in the US, minority persons (including AAs) compared to Whites tended to exhibit a more severe profile of AD at the time of presentation [15]. Despite such relatively slower rate of AD progression, AA MCI and incident AD patents experienced greater decline in body mass index (BMI) compared to normal controls [16]. While the biologic explanation for the lower rates of cognitive decline in AAs needs further elucidation, an enriched social network has been proposed as a possible explanation [17]. Collectively, a higher incidence and greater rate of cognitive decline in MCI and AD-afflicted AAs, delayed diagnosis, lower rate of cognitive decline once AD occurs together with an accelerated weight loss suggest that the overall prevalence of AD in this population will reach epidemic proportions in the coming decades. Decreased overall wellness and increased health disparity are notable consequences. Given the effects of socioeconomic variables and access to health care on these important health indicators, such consequences may become blurred by regional variations. In support of this view, we recently reported that racial differences in AD or dementia mortality varied by regions in the United States (Table 1) [12, 18]. A fundamentally important implication of these observations is that other factors at the environment or genetic level may contribute to higher incidence and prevalence of AD in AAs than in Whites. Increased CVD risks and low levels of physical activity may explain some of these differences.

At the genetic level, APOE gene is the most consistent nondeterministic genetic risk factor for AD. Its contributions to AD risk are graded across alleles (ε2, ε3 and ε4), with ε4 conferring the highest risk [19, 20]. While many believed that the contributions of the ε4 allele to AD risk are similar across populations [21, 22], others have reported a lower associated AD risk in AAs than in Whites [23, 24]. Using pooled samples from the MIRAGE, Alzheimer’s Disease Neuroimaging Initiatives (ADNI), Canadian Study on Genetics of Alzheimer’s Disease Association (GenADA), and National Institute on Aging-Late-Onset Alzheimer’s Disease Family Study (NIA-LOAD) data, we reported that the presence of ε4
allele significantly and exponentially associated with AD in AAs in a dose-dependent manner. However, the odds ratio estimates in ε4 carriers showed lower rates of AD in AAs compared to Whites (63.1 percent versus 67 percent). Conversely, we also observed a higher occurrence of ε4 in AA controls than White controls (40.1 percent versus 29.1 percent), respectively [25]. These suggest that the ε4 allele of the APOE gene may interact with other risk factors to cause a differential AD risk in AAs compared to Whites. Interestingly, AAs also have increased CVD risks such as hypertension, diabetes, and hypercholesterolemia. Evidently, key interactions of APOE gene with CVD risk such as lipids, inflammation, glucose homeostasis, and lifestyle factors in these populations must be considered [26]. Such factors may lend themselves to interventions capable of attenuating AD risk in AAs and other populations at risk.

At the environment level, growing evidence indicates that aerobic fitness can reduce AD risk in predominantly White samples. However, these advantageous effects of exercise are yet to be validated in a relatively more sedentary AA sample [27]. Given the higher rates of AD in AAs than in Whites and the lack of substantive differences in AD neuropathology [28, 29], it is likely that AA mild AD patients will also benefit from the advantageous effects of aerobic fitness. In addition to the public health imperative, such intervention may ameliorate the physical, emotion, and economic burden associated with AD. All of these effects will benefit society at large.

4. Rationale for Dementia Prevention

Whereas, it is established that the preservation of neurocognitive function among those showing earliest signs and symptoms of AD can attenuate the burden associated with the disease; unfortunately, this benefit and the national goals of Healthy People 2010 cannot be realized without an efficient AD prevention strategy. Moreover, while medical treatment after disease onset may reduce disease progression and mortality, eventually, increases in disease prevalence will substantially escalate total disease burden and healthcare cost for the population. Though the current approach to symptomatic treatment of AD may not be cost-effective in populations with excessive rates of disease such as AAs, a low-cost low-risk intervention strategy with dual applicability for primary and secondary prevention is likely to be advantageous.

The goal of this paper, therefore, is to enhance scientific discussion on the role of CVD risk in the development of AD and related dementias and to add clarity to the clinical utility of fitness adaptation in preventing AD in those at risk. However, significant uncertainty in disease progression from prodromal to symptomatic AD raises an important question of whether intervention should be directed at the fully characterized MCI or AD clinical phenotypes. Because of the present impracticality of reversing neuronal death underlying the AD phenotype, interventions are likely to yield the most benefit if initiated at the earliest possible stage as in pre-MCI. Indicators of such timely intervention may include notable endophenotype such as decreasing cerebrospinal fluid (CSF) levels of Aβ that precede the emergence of the MCI clinical phenotype. If confirmed in randomized clinical trials, aerobic fitness can become an effective public health tool to combat AD risk. Such a low-cost low-risk strategy is likely to reduce the burden of disease and optimize the well-being of older adults at increased AD risk.

5. Cardiovascular Disease Risk in AD Development

Stroke and Alzheimer’s type dementia increase at comparable rates with advancing age. Atherosclerosis, hypertension, diabetes mellitus, and lipids are major CVD risk factors shown to be associated with AD [30]. Recently, Arvanitakis and colleagues reported an association of diabetes with semantic memory impairment in both Blacks and Whites [30]. The Rotterdam population-based prospective study that examined approximately 8000 subjects over age 55 for the frequency of lifetime risk of dementia and its subtypes, including AD, showed an increase in the prevalence of atherosclerosis in both vascular dementia and AD [31]. Also, compilation of autopsy reports on AD brains indicate, that approximately 60–90 percent of the cases exhibited variable cerebrovascular pathology synonymous with CVD [28–32]. In AD cases ascertained by the presence of amyloid angiopathy, endotheial degeneration, and periventricular white matter lesions at autopsy, Van Nostand showed that ~ 1/3rd had evidence of cerebral infarction [33]. However, in a study to examine the relationship of important AD intermediate phenotype such as differences in brain volume, hippocampal volume and cerebrovascular risk factors, and APOE4 among MCI subtypes, He and colleagues found CVD risk factors to be more closely related to nonamnestic MCI and vascular dementia; though emphasized that the biological differences between amnestic (AD group) and nonamnestic (presumed vascular etiology) were very subtle [34]. Given these observations, it is possible that CVD risks plays a greater role in cognitive decline in older AAs compared to Whites. In support of this view, Brickman et al. demonstrated more severe white matter hyperintensity (WMH) burden in AAs and Hispanics compared to Whites [35]. In particular, vascular disease was associated with relatively smaller brain volume and higher WMH burden in AAs. Others have also demonstrated greater degree of psychomotor impairment, a surrogate for higher cerebrovascular burden in AAs than in Caucasians [36]. Collectively, these reports indicate that CVD risk factors may also influence cognitive loss, particularly in AAs who suffer a greater burden of CVD risk and related brain pathology.

Regardless of whether increased CVD risk burden culminates into vascular dementia, enables or directly promote AD pathology [37–42], with or without interactions with age-associated decline in health status [43], interventions directed at reducing CVD risk factors may attenuate declining cognitive dexterity especially in older AAs. Despite the evidence showing a higher degree of CVD risks and cerebrovascular pathology in AAs, data is lacking on whether aerobic fitness-induced reduction in CVD risk can concomitantly reduce AD risk in this population. Given that AAs suffer a high CVD-related morbidity, they are likely to benefit from CVD risk reduction measures. Collection of prospective data on putative CVD mediators of AD and their
susceptibility to fitness adaptation will elucidate its clinical utility in ameliorating AD risks in AAs and other populations.

6. Mechanisms by Which Cardiovascular Disease Risk Can Influence AD

6.1. Association of Total Cholesterol with AD Risk. Disorder of brain cholesterol metabolism has been associated with all principal pathological features of AD such as synaptic transmission [44], amyloid [45], and tau pathology [44]. Lipids and lipid peroxidation products have important roles in the homeostasis of the central nervous system [46]. In animal and in vitro studies, Golde and colleagues showed that overexpression of cholesterol resulted in the formation of amyloid β and contributed to the degradation of neurons and subsequent cognitive impairment [47]. Also, lipid transport genes and vascular changes associated with peripheral dyslipidemia have been associated with an increased risk of AD. This indicates that lipids may be involved in the pathogenesis of neurodegeneration and related dementias. Alternatively, lack of cholesterol supply to the neurons via lipoprotein transport may cause failure of neurotransmission and synaptic plasticity [48]. However, because almost all brain cholesterol is a product of local synthesis, with brain blood barrier efficiently protecting it from exchange with lipoprotein cholesterol in the systemic circulation [49], serum cholesterol may not accurately reflect the related AD risk. Moreover, the bimodal relationship of serum cholesterol with health may contribute to the inconsistencies of reports on the association of cholesterol with cognitive health, especially when the protective influence of HDL-C is not considered.

6.2. Association of High-Density Lipoprotein Cholesterol with AD and CVD Risk. HDL-C is an important risk factor for CVD [50, 51]. As with CVD risk, the contribution of HDL-C to AD risk is increasingly recognized. HDL-C functions to both keep its lipid components soluble and also provide an efficient mechanism for their transportation through plasma and to or from the tissues. Low HDL-C, together with suboptimal transport system in humans, results in gradual deposition of lipid (especially cholesterol) in tissues causing arteriolar narrowing and chronic cerebral oxygen deprivation [52].

6.3. HDL-C Is the Predominant Lipoprotein in Human Brain Circulation, and Its Low Levels Have Been Associated with Impaired Memory [53–55]. For example, Wolf and colleagues recently showed that low levels of HDL-C and not LDL or total cholesterol levels were associated with hippocampus atrophy in aged humans [56]. Unlike total cholesterol, HDL-C brain level correlates with its plasma concentration. This evidence suggests that low levels of HDL-C may play an important role in AD risk. Beyond the direct effect of low HDL-C on arteriolosclerosis, high HDL-C may conversely influence AD risk in three other important ways: (i) mediation of reduced inflammatory cytokines which is central to arteriolar narrowing; (ii) through its interaction with Aβ to form soluble HDL-C-Aβ complex (Figure 2); (iii) its antioxidant property.

6.4. Evidence of Anti-Inflammatory Effects of HDL-C. In support of HDL-C anti-inflammatory effects, Cockerill and colleagues showed that, in physiological concentration, isolated plasma HDL-C inhibited tumor necrosis factor-α (TNF-α) or interleukin-1 (IL-1) and reduced leukocyte adhesion molecules in a concentration-dependent manner (Figure 2) [57]. Others have reported increased markers of inflammation with low HDL-C levels [58]. Therefore, as the predominant lipoprotein in the brain circulation, the anti-inflammatory effects of high HDL-C may play an active role in reducing vascular inflammation and arteriolosclerosis of the cerebral circulations. This may enhance brain oxygenation and preserve neurocognitive dexterity.

6.5. Evidence of Antiamyloid Deposition Effects of HDL-C. The interaction of HDL-C with Aβ is consistent with its neuroprotective effects. For example, HDL-C attenuates the aggregation and polymerization of Aβ protein (Figure 2) [59]. Using thioflavin T fluorescence, Olesen and Dago showed that HDL-C reduced amyloid formation in vitro. Additionally, the association of HDL-C with Aβ was also recently demonstrated by Koudinov et al. who isolated HDL-Aβ complexes from CSF [60]. More support for the direct effects of HDL-C on Aβ was evidenced by studies showing that Aβ mediated the cellular uptake of lipoproteins [61], and that HDL-C induced increases in the cellular degradation of Aβ in cultured microglia [62]. Its neuroprotective property against Aβ was also demonstrated by Farhangrazi et al., who showed that the neurotoxic effect of Aβ in cortical cell cultures became attenuated in the presence of high levels of HDL-C [63]. It is therefore likely that HDL-C exerts a significant antiamyloid effect that may be susceptible to lifestyle alteration.

6.6. Evidence of Antioxidant Effect of HDL-C. Growing evidence suggests that oxidative damage is implicated in neuronal degeneration that occurs in AD brains [64, 65]. High-plasma HDL-C particles can also exert antioxidant activity and have the capacity to protect low-density lipoprotein (LDL) against oxidative stress [66]. Though the exact mechanism by which HDL-C exerts antioxidant effects needs further clarification, its role as a transporter of enzymes exerting antioxidative activity such as paraoxonase (PON) [67], platelet-activating factor acetylhydrolase (PAF-AH) [68] and lecithin-cholesterol acyltransferase (LCAT) [69] must be noted. Moreover, intrinsic antioxidative property of HDL-C subfraction is deficient in the presence of low HDL-C phenotype and amplified by low number of circulating HDL-C particles. Indeed, this dysfunctionality is closely related to elevated oxidative stress evidenced by breakdown products of arachidonic acid such as plasma isoprostane.

In summary, given the effects of high HDL-C levels on the biochemical properties of Aβ and its antioxidant property, it is likely that HDL-C plays a direct role in brain amyloid deposition and AD risk. Because high HDL-C can reduce inflammation, enhance lipid metabolism, and therefore reduce arteriolosclerosis and enhance brain perfusion, it is likely to be important for optimal neurocognitive function. Fortunately, HDL-C is susceptible to the effects of aerobic
6.7. Association of Inflammation with AD Risk. Though considerable uncertainty exists on the exact role of the inflammation in AD, many studies have documented the association of inflammatory markers such as CRP and IL1a with AD. The role of inflammation has become even more evident with recent studies on microglia. Microglia, a distinct population of brain-resident macrophages, is indicative of ongoing chronic inflammation in AD. In support of anti-inflammatory role of microglia, Minagar and McGee demonstrated its activation in regions of the brain showing AD pathology [71, 72]. Building on earlier observations, Frank et al. recently examined the association of inflammation with the neuropathology of AD and showed that microglia are present in close association with aggregated types of Aβ plaques and around neurofibrillary tangles [73]. Frank et al. also showed that microglia-derived factors including reactive oxygen species and tumor necrosis factor-α (TNF-α) are neurotoxic [73]. Neuronal damage by microglia can also occur when activated microglia and reactive astrocytes surrounding intracellular deposits of Aβ protein initiate an inflammatory response [74]. Often, this type of response is characterized by local cytokine-mediated acute phase response and activation of the complement cascade [74]. However, studies on the effects of anti-inflammatory agents on AD risk are inconclusive. For example, a retrospective study of long-term users of nonsteroidal anti-inflammatory drugs showed a lower incidence of AD in this population [75]. Conversely, recent clinical trials found no benefit to the use of nonsteroidal anti-inflammatory drugs (NSAIDs) [76, 77]. Since the actual dose, duration, and period of protective NSAID use are unknown, these negative results are hardly definitive. Further, many of these studies did not account for genetic mediators of inflammatory markers. Notable among such markers are interleukins and...
C-reactive protein (CRP). We and others have shown that aerobic fitness either independently or interactively with its genetic mediators can reduce CRP level [78, 79]. Whether training-induced reductions in inflammation and CRP levels translate into improvements in cognitive performance has not been studied. In our currently ongoing pilot clinical trial, we will further delineate the role of inflammation in AD, its association with HDL-C and Aβ protein, and whether exercise-related changes in inflammatory markers are associated with neurocognitive measures that are used in this study. Demonstration of concomitant reduction in inflammatory markers, with improvements in neurocognitive function after aerobic exercise training, will be important evidence supporting the role of inflammation in AD. This would be indicative of the susceptibility of AD risk factors to aerobic fitness.

7. Association of Hypertension with AD Risk

Growing evidence indicates a causal role of hypertension for cognitive decline of the Alzheimer’s type dementia (Figure 2) [80, 81]. A few longitudinal studies have also emphasized a connection between high blood pressure in midlife and dementia in late life [80, 81]. Recently, Korf and colleagues reported an association of systolic blood pressure (SBP) and pulse pressure (PP) with medial temporal lobe atrophy (MTA), a hallmark of AD, in individuals with late onset dementia, especially when coexisting with white matter changes [82]. These reports indicate that CVD risk factors including hypertension may also influence AD risk. Our own data from the NHANES III support these observations. Though the optimal BP for cognitive performance remains poorly defined and evidence is emerging on the effects of CVD-related genes such as ENOS and ACE on AD, the combined effects of hypertension and genetics on neurocognitive function need clarity. Like many other CVD-related AD risk, considerable evidence suggests that fitness adaptation can reduce blood pressure [83–85]. However, whether a concomitant improvement in neurocognitive performance occurs with aerobic fitness-related improvements in blood pressure has not been examined. Even if very small cognitive benefit accrues from blood pressure reduction, substantial gains can be realized, given the relatively high prevalence of hypertension in the United States and in the World.

8. Association of Hypoxia and Glucose Homeostasis with AD Risk

Neurons are highly vulnerable to impairments of oxygen homeostasis because of their singular dependency on oxygen. Though the human brain averages about 2 percent of body mass, it utilizes 15 percent of cardiac output and 20 percent of respiratory oxygen uptake. In neural cells in primary culture and in the hippocampus using in vivo models, both cycloo-2 (COX2) and presenile-1 (PS1) are induced after only about 5 minutes of hypoxia [86, 87]. Cell cultures and transgenic models also suggest an interactive relationship of hypoxia with microglia activation, neuroinflammation, reduced neuronal function, and apoptosis [88–90]. These reports are indicative of the independent and collective roles of CVD risk factors and, importantly hypoxia in AD risk.

Changes in brain glucose metabolism are associated with AD [91, 92], and the upregulation of glucose metabolism has been demonstrated to activate the transcription of hypoxia inducible factor (HIF-1) [93]. HIF-1 is a heterodimeric transcription factor comprised of two subunits, HIF-1α and HIF-1β. In normoxic state, the binding and transcription of hypoxia-inducible genes do not occur [94]. HIF-1 mediates the adaptation of cells to hypoxia and hypoglycemia by upregulating genes involved in glucose transport and glycolysis [93]. Blunted HIF-1 response to hypoxia has been shown to promote Aβ formation and changes in glucose metabolism. Together, this evidence suggests that inflammation, acting in concert with HIF-1, and glucose metabolism may play an active role in brain cellular damage and ultimately AD. Fortunately, fitness adaptation can enhance glucose uptake, increase cerebral perfusion and possibly favorably regulate the activation of HIF-1. However, there is no randomized, controlled experiment linking aerobic fitness to improvements in these intermediate phenotypes or neurocognitive function. Large-scale clinical trials are needed to determine whether fitness-related improvements in brain perfusion are effective intervention strategies to reduce AD risk.

9. Exercise Effects on Cognitive Function

9.1. Fitness Training Is Associated with Improved Cognitive Health in Cross-Sectional and Few Prospective Studies. Cross-sectional [95, 96], longitudinal [97], and meta-analyses have demonstrated that improvements in cardiovascular fitness can improve cognitive function in humans [98, 99]. For example, Larson recently showed a <3 times/week exercise to be related to increased risk of AD compared to >3 times/week exercise [100]. Others have reported an inverse relationship of AD with the number of physical activities performed. [96] In a study of leisure-time physical activity during midlife and dementia, Rovio et al. reported a reduced risk of AD in those with higher levels of physical activity [95]. These studies suggest a significant association of physical activity with later reduction in neurocognitive function and dementia. Notwithstanding the mostly beneficial effects of exercise observed in the majority of studies, limitations such as self-reported data; failure to distinguish between aerobic and no-aerobic activities; failure to assess exercise duration, intensity, and frequency; differences in the volume of exercise that is beneficial likely resulted in significant variability among studies.

To obviate the limitation inherent in cross-sectional studies, a few prospective studies have examined the effects of fitness adaptation on memory. Using meta-analyses of 18 published studies, Colcombe and Kramer found a beneficial effect of fitness training on an array of neurocognitive processes in nondemented older adults [99]. In a ~7-year prospective study of 5925 older women, Yaffe et al. demonstrated a 37% reduction in the odds of cognitive decline in 3rd quartile compared to 1st quartile of physical activity [101]. In another prospective study, Barnes and colleagues reported better
cardiorespiratory fitness at baseline to be associated with less cognitive decline at ~6-year followup [102]. A recent 24-week randomized placebo control trial of an unsupervised physical activity intervention study in MCI-like subjects by Lautenschlager et al. revealed an improvement of 1.0 points in ADAS-cog for exercisers, and a deterioration of 1.3 for controls yielded a total of 2.3 point difference between the intervention and control groups over 6 months. Interestingly, the cognitively beneficial effects of aerobic fitness remained at 18-month followup [103]. Though these prospective studies add substantially to the current knowledge and the directionality of the relationship of aerobic fitness with neurocognitive function, data is lacking on AAs. Importantly, a more rigorous randomized controlled trial in MCI patients is needed to establish causality and to clearly delineate the overall volume of exercise that is beneficial. In spite of the skepticism on the relatively large aerobic fitness-related effect size reported in many studies, the multiple levels at which exercise can influence AD risk support such observations.

10. Mechanism by Which Exercise Influences Neurocognitive Function

Mechanism by which aerobic fitness affects neurocognitive health is yet to be clearly elucidated. Despite the evidence showing an association between exercise engagement and improvements in AD biomarkers in cognitively normal older adults [104] and reports of increased aerobic fitness-related increases in brain volume in some studies [105–107], the underlying biological mechanism for these effects needs further clarifications. Given the available evidence, it appears that the effects of exercise on neurocognitive function are mediated through several important pathways. Dyslipidemia, especially low HDL-C levels, inflammation, deranged glucose homeostasis, and endothelia dysfunction are precursors of arteriolosclerosis, decreased cerebral perfusion and cerebral oxygen deprivation, all of which may increase AD risk [108, 109]. Aerobic fitness can increase HDL-C, reduce inflammation [78], improve glucose homeostasis [110], and reduce arteriolosclerosis. Because these benefits can enhance brain perfusion and improve brain oxygenation, likely benefits include reduction in AD risk [111] (Figure 1).

Our own analysis of the data from NHANES III supports the advantageous effects of high levels of HDL-C (Figures 3(a) and 3(b)). Because exercise can cause reduction in stress hormone levels known to impair cognitive function [112]; promote neurotrophic changes, nerve cell regeneration, and neurotransmitter repletion, all of which may enhance cognitive performance [113, 114], these effects are likely involved in the mechanism by which aerobic fitness affects neurocognitive function. Since the evidence suggests that exercise can increase solubility of Aβ through increases in HDL-C [62] and favorably regulate hypoxia inducible factor (Figures 1 and 3), these effects may represent alternative important mechanism by which exercise exerts its advantageous effect on neurocognitive function. Training-induced improvements in these putative AD risk factors may precede more distal effects of fitness adaptation such as increased activity in the frontal and parietal regions of the brain and increased gray matter volume in the frontal and superior temporal lobe reported by Colcombe and Kramer, respectively [115, 116]. Collectively, these observations indicate that aerobic fitness may attenuate neurocognitive loss in humans.

11. Limitations of Knowledge on the Effects of Exercise on Neurocognitive Function

While most of the studies on the effects of aerobic fitness on cognition are indicative of its beneficial effects, few limitations of these studies must be pointed out. First, most have not used a standardized exercise protocol, none used randomized controlled design in MCI or mild AD patients. While the evidence supports an overlap of CVD risk with AD risk and the responsiveness of CVD risk factor to fitness adaptation, most of the intervention studies thus far have not explored CVD risk reduction as the mechanism for improvement in cognitive performance. A prospective randomized controlled trial of aerobic fitness with biomarkers and neuroimaging will inform the establishment of causality, and help determine the volume of exercise that is beneficial. Notably, it will lay the groundwork for the determination of the role of genetics in aerobic fitness-related effects and the mechanism by which fitness affects neurocognitive function.

12. Apolipoprotein E Gene as a Modifier of AD Risk

12.1. APOE Is a Risk Factor for AD. The evidence suggests that the APOE gene, especially the ε4 subtype, is a major risk factor for sporadic and late-onset Alzheimer’s dementia [117, 118]. There are three known common isoforms of APO (E2, E3, and E4) in humans encoded by the different alleles ε2, ε3, and ε4. It acts as a receptor of ligands, signifying that intraneuronal APOE may be a mechanism by which APOE influences neuronal repair, regeneration, and survival. Further, APOE can interact with β-amyloid and tau proteins that are central to the pathogenesis of Alzheimer’s dementia. Specifically, the presence of APOE lipoprotein in cerebral blood vessels laden with amyloid β-protein (A-β) [119] is indicative of the importance of Apolipoprotein in the pathogenesis of AD.

12.2. APOE Gene May Influence AD Risk through Its Effects on High-Density Lipoprotein Metabolism. Similar to the role of the ε4 allele APOE gene in the pathogenesis of Alzheimer’s dementia, its association with elevated lipid levels [120] and atherosclerosis have also been reported [121]. Genetic variation at the APOE locus can also influence atherogenesis through its effects on HDL-C subfractions. APOE affects the hepatic binding, uptake, and catabolism of several classes of lipoproteins associated with HDL-C subfractions [122, 123]. The ε2 and ε4 alleles of the APOE gene are associated with higher and lower HDL-C subfractions, respectively, among different ethnic subgroups and across regional boundaries [124, 125]. Together, these observations suggest that an individual’s genetic makeup, especially at the APOE, locus may interact with the environment to influence HDL-C levels. Because of the importance of apolipoprotein to HDL-C metabolism and its susceptibility to the influence of APOE
12.3. African Americans: The Role of APO E in AD Risk. Evidence from protein binding indicates that Aβ interacts with APOE in an isoform specific manner, and fibril formation of Aβ is enhanced by the presence of ε4 allele of the APOE gene. In its physiologic state, APOE is normally present in the brain in association with HDL-C-like particles. In view of the important role of the ε4 allele and its overrepresentation in AAs, a proportionately higher ε4-associated AD risk in AAs would be expected. However, some evidence suggests the converse.

The interaction of HDL-C with APOE provides a useful insight into the reduced ε4 allele-associated AD risk, and the slower rate of AD progression in AAs. Consistently, higher levels of HDL-C have been shown in AAs than elderly Caucasians [126, 127]. In the presence of HDL-C particle, Olesen and colleagues found no direct effect of APOE on amyloid formation [59]. This suggest that, though ε4 may increase the spontaneous amyloid formation of Aβ, HDL-C-bound Aβ appear to decrease amyloid formation as a result of strong amyloid inhibitory effect of HDL-C. Alternatively, ε4 allele may influence amyloid formation by affecting the levels of HDL-C-like particles in the brain. Therefore, because AAs have relatively higher levels of HDL-C, it is possible that HDL-C interacts with APOE to reduce the ε4 allele-related AD risk and, importantly, lower the rates of disease progression in this population.

12.4. Combined Effect of APOE Gene and Exercise Training on HDL-C in AAs. Increased levels of HDL-C and HDL2-C are the most significant changes in lipid and lipoprotein levels that occur following aerobic exercise training [128, 129]. Results from exercise training studies show higher levels of HDL-C after exercise in most older Whites [130, 131]. Such highly variable responses to a standardized exercise training intervention may implicate genetic factors as contributors.

Across all adult age groups, habitual levels of physical activity are significantly lower in AAs than in Caucasian Americans for both men and women [132, 133]. A sedentary lifestyle among older AAs leads to obesity and higher triglycerides (TG) and LDL-C, but lower HDL-C [134, 135]. Conversely, exercise training can reduce TG and LDL-C and increase HDL-C. Following 10 weeks of aerobic exercise training, Doshi et al. reported an 8% reduction in cholesterol/HDL-C ratio in older AAs, independent of changes in body composition [136]. Conversely, a study in South African Blacks found no significant change in HDL-C levels after exercise training [137]. These studies suggest that exercise training may increase HDL-C levels in some AAs. Significant interactions with APOE genotype are one possible mechanism by which this can occur. Interestingly, our own standardized aerobic exercise training data showed fitness-related increases in the levels of HDL-C particle size and concentration in ε2/3 and ε4 AAs, though to a lower extent in ε4 carriers. Therefore, APOE and other genetic markers may account for some of the disagreements among studies.

In our currently ongoing pilot study, we will collect prospective data on APOE, HDL-C (particle size and concentration), other biomarkers, neurocognitive function, and neuroimaging. Data on the interactive effects of HDL-C, APOE, and aerobic exercise training on neurocognitive function, will be used to inform the power calculation for a full-scale clinical trial to determine the mechanism by which aerobic-fitness affects neurocognitive function.

12.5. Summary of Current Knowledge, Gaps. The evidence highlights the central role of CVD risk and chronic cerebral oxygen deprivation to neurocognitive health. Importantly, disorders of brain lipid metabolism are associated with all principal pathological features of AD such as synaptic
transmission [44], inflammation, amyloid [45], and tau pathology [44]. HDL-C is the predominant lipoprotein in human brain circulation, and its low levels can impair memory [53–55]. Unlike total cholesterol, its brain levels reflect blood level. Low levels of HDL-C is associated with hippocampal atrophy in aged humans [56] and therefore likely to be involved in the effects of lipids on cognitive function. Because HDL-C can also increase the cellular degradation of Aβ, and decrease Aβ-induced neurotoxicity in neural culture, it is likely that HDL-C also plays an important role in the biochemical properties of Aβ amyloid formation, and AD. Aerobic exercise can increase HDL-C, reduce inflammation, improve glucose homeostasis, and enhance cerebral perfusion.

Cross-sectional and few prospective studies in predominately normal Whites samples suggested that aerobic fitness can enhance cognitive function [96, 102, 116, 125, 138]. The outcome of these studies are hardly definitive, and the mechanism by which fitness adaptation affect cognitive function remains to be fully elucidated. Though we and others have shown that exercise can increase HDL-C (Figure 3), the effect of aerobic fitness-induced changes in HDL-C on preservation of neurocognitive function is yet to be examined. Further, whether these changes correlate with changes in cerebral glucose homeostasis is not known. Future studies must focus not just on CVD risk factors and brain infarcts, but also on its surrogates such as increased vascular resistance and chronic cerebral oxygen insufficiency with or without infarcts as well as decreased oxygenation associated with age-related decline in pulmonary function. The role of HIF in these cascades of events must also be considered.

Consistently, the APOE gene has been shown to influence both HDL-C metabolism and independently AD risk. In view of the susceptibility of HDL-C to aerobic fitness and the importance of APOE gene to HDL metabolism, it is vital to examine the effects of APOE on AD risk and its relationship to aerobic fitness-induced increases in HDL-C. Given potential multiple ways in which exercise may improve cognitive performance and therefore reduce AD risk and the relatively large aerobic fitness-related effect size reported in many studies, clinical trials are needed to determine the effect of aerobic exercise-training on cognitive function in patients with mild AD, notwithstanding the recent NIA consensus statement on general lack of progress.

The demonstration of training-related improvements in neurocognitive function and regional cerebral glucose utilization independent of or interactively with APOE gene would provide momentum for a large-scale clinical trial. A concomitant improvements in HDL-C and inflammatory markers will significantly advance knowledge of the mechanism by which aerobic fitness affects neurocognitive function. A study with the advantage of an experimental design, the use of a control group, and ability to examine the contribution of putative CVD risk factors to AD development and progression is highly desirable. In addition to informing the mechanism by which aerobic fitness can enhance neurocognitive vitality in humans in a subsequent large-scale clinical trial, it will help quantify the effects of aerobic fitness on biomarkers, neurodegeneration, and brain glucose homeostasis. For populations such as AAs with disproportionately higher rates of CVD risk and pathology, a confirmatory large scale trial will validate the role of aerobic fitness as an adjunct treatment to ameliorate the physical, psychological, and economic burden associated with AD at individual levels. In addition to providing evidence leading to a scientific basis for a change in health policy and standard of care, society is also likely benefit from reduction in the economic burden.

Acknowledgments

Dr. T. O. Obisesan was supported by Career Development Award no. AG00980, research award no. RO1-AG031517 from the National Institute on Aging, and Research Award no. 1UL1RR03197501 from the National Center for Research Resources.

References

[1] G. W. Small, P. V. Rabins, P. P. Barry et al., “Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society,” Journal of the American Medical Association, vol. 278, no. 16, pp. 1363–1371, 1997.
[2] K. Ritchie, “Dementia in the elderly,” Neurology, vol. 45, no. 11, pp. 2112–2113, 1995.
[3] D. A. Evans, H. H. Funkenstein, M. S. Albert et al., “Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported,” Journal of the American Medical Association, vol. 262, no. 18, pp. 2551–2556, 1989.
[4] D. A. Evans, “Estimated prevalence of Alzheimer’s disease in the United States,” Milbank Quarterly, vol. 68, no. 2, pp. 267–289, 1990.
[5] L. E. Hebert, L. A. Beckett, P. A. Scherr, and D. A. Evans, “Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050,” Alzheimer Disease and Associated Disorders, vol. 15, no. 4, pp. 169–173, 2001.
[6] R. Brookmeyer, S. Gray, and C. Kawas, “Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset,” American Journal of Public Health, vol. 88, no. 9, pp. 1337–1342, 1998.
[7] E. M. Gutterman, J. S. Markowitz, B. Lewis, and H. Fillit, “Cost of Alzheimer’s disease and related dementia in managed-care,” Journal of the American Geriatrics Society, vol. 47, no. 9, pp. 1065–1071, 1999.
[8] W. Thies and L. Bleiler, “Alzheimer’s disease facts and figures,” Alzheimer’s & Dementia, vol. 7, pp. 208–244, 2011.
[9] J. R. Murrell, B. M. Price, O. Baijewu et al., “The fourth Apolipoprotein E haplotype found in the Yoruba of Ibadan,” American Journal of Medical Genetics, Part B, vol. 141, no. 4, pp. 426–427, 2006.
[10] A. Ogumi, K. S. Hall, O. Gureje et al., “Risk factors for incident Alzheimer’s disease in African Americans and Yoruba,” Metabolic Brain Disease, vol. 21, no. 2–3, pp. 235–240, 2006.
[11] H. B. Lee, K. A. Richardson, B. S. Black, A. D. Shore, J. D. Kasper, and P. V. Rabins, “Race and cognitive decline among community-dwelling elders with mild cognitive impairment: findings from the memory and medical care study,” Aging & Mental Health. In press.
S. Gao, J. T. Nguyen, H. C. Hendrie et al., “Accelerated weight loss and incident dementia in an elderly African-American cohort,” *Journal of the American Geriatrics Society*, vol. 59, no. 1, pp. 18–25, 2011.

L. L. Barnes, C. F. Mendes De Leon, R. S. Wilson, J. L. Bienias, and D. A. Evans, “Social resources and cognitive decline in a population of older African Americans and whites,” *Neurology*, vol. 63, no. 12, pp. 2322–2326, 2004.

R. F. Gillum and T. O. Obisesan, “Differences in mortality associated with dementia in U.S. blacks and whites,” *Journal of the American Geriatrics Society*, vol. 59, no. 10, pp. 1823–1828, 2011.

J. Dallongeville, S. Lussier-Cacan, and J. Davignon, “Modification of plasma triglyceride levels by apoE phenotype: a meta-analysis,” *Journal of Lipid Research*, vol. 33, no. 4, pp. 447–454, 1992.

A. S. Leon, K. Togashi, T. Rankinen et al., “Association of apolipoprotein E polymorphism with blood lipids and maximal oxygen uptake in the sedentary state and after exercise training in the HERITAGE Family Study,” *Metabolism*, vol. 53, no. 1, pp. 108–116, 2004.

L. A. Farrer, L. A. Cupples, J. L. Haines et al., “Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: a meta-analysis,” *Journal of the American Medical Association*, vol. 278, no. 16, pp. 1349–1356, 1997.

R. C. Green, L. A. Cupples, R. Go et al., “Risk of dementia among white and African American relatives of patients with Alzheimer disease,” *Journal of the American Medical Association*, vol. 287, no. 3, pp. 329–336, 2002.

D. A. Evans, D. A. Bennett, R. S. Wilson et al., “Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status,” *Archives of Neurology*, vol. 60, no. 2, pp. 185–189, 2003.

A. Sahota, M. Yang, S. Gao et al., “Apolipoprotein E-associated risk for Alzheimer’s disease in the African-American population is genotype dependent,” *Annals of Neurology*, vol. 42, no. 4, pp. 659–661, 1997.

M. W. Logue, M. Schu, B. N. Vardarajan et al., “A comprehensive genetic association study of Alzheimer disease in African Americans,” *Archives of Neurology*, vol. 68, no. 12, pp. 1569–1579, 2011.

H. C. Hendrie, I. Murrell, S. Gao, F. W. Unverzagt, A. Ogunniyi, and K. S. Hall, “International studies in dementia with particular emphasis on populations of African origin,” *Alzheimer Disease and Associated Disorders*, vol. 20, no. 2, pp. 842–S46, 2006.

[21] L. A. Farrer, L. A. Cupples, J. L. Haines et al., “Epidemiological studies in the HERITAGE Family Study,” in *International studies in dementia with implications in Alzheimer’s disease at initial presentation at an urban alzheimer’s disease center,* *American Journal of Geriatric Psychiatry*, vol. 19, no. 5, pp. 430–439, 2011.

[22] R. F. Gillum and T. O. Obisesan, “Differences in the clinical characteristics of Alzheimer’s disease at initial presentation at an urban Alzheimer’s disease center,” *Annals of Neurology*, vol. 68, no. 12, pp. 1569–1571, 1997.

[23] V. Hachinski and D. G. Munoz, “Cerebrovascular pathology in Alzheimer’s disease: cause, effect or epiphenomenon?” *Annals of the New York Academy of Sciences*, vol. 826, pp. 1–6, 1997.

[24] L. L. Barnes, C. F. Mendes De Leon, R. S. Wilson, J. L. Bienias, and D. A. Evans, “Change in cognitive function in Alzheimer’s disease in African-American and white persons,” *Neuroepidemiology*, vol. 26, no. 1, pp. 16–22, 2004.

[25] M. W. Logue, M. Schu, B. N. Vardarajan et al., “A comprehensive genetic association study of Alzheimer disease in African-American and white individuals,” *Archives of Neurology*, vol. 63, no. 1, pp. 87–90, 2006.

[26] H. C. Hendrie, I. Murrell, S. Gao, F. W. Unverzagt, A. Ogunniyi, and K. S. Hall, “International studies in dementia with particular emphasis on populations of African origin,” *Alzheimer Disease and Associated Disorders*, vol. 20, no. 2, pp. 842–S46, 2006.
[42] R. Altman and J. C. Rutledge, “The vascular contribution to Alzheimer’s disease,” *Clinical Science*, vol. 119, no. 10, pp. 407–421, 2010.

[43] X. Song, A. Mitnitski, and K. Rockwood, “Nontraditional risk factors combine to predict Alzheimer disease and dementia,” *Neurology*, vol. 77, no. 3, pp. 227–234, 2011.

[44] A. R. Koudinov and N. V. Koudinova, “Essential role for cholesterol in synaptic plasticity and neuronal degeneration,” *The FASEB Journal*, vol. 15, no. 10, pp. 1858–1860, 2001.

[45] S. Bodovitz and W. L. Klein, “Cholesterol modulates α-secretase cleavage of amyloid precursor protein,” *Journal of Biological Chemistry*, vol. 271, no. 8, pp. 4436–4440, 1996.

[46] M. M. Mielke and C. G. Lyketsos, “Lipids and the pathogenesis of Alzheimer’s disease: is there a link?” *International Review of Psychiatry*, vol. 18, no. 2, pp. 173–186, 2006.

[47] T. E. Golde and C. B. Eckman, “Cholesterol modulation as an emerging strategy for the treatment of Alzheimer’s disease,” *Drug Discovery Today*, vol. 6, no. 20, pp. 1049–1055, 2001.

[48] A. R. Koudinov, T. T. Berezov, and N. V. Koudinova, “The levels of soluble amyloid beta in different high density lipoprotein subfractions distinguish Alzheimer’s and normal aging cerebrospinal fluid: implication for brain cholesterol pathology?” *Neuroscience Letters*, vol. 314, no. 3, pp. 115–118, 2001.

[49] N. Bogdanovic, L. Brettillon, E. G. Lund et al., “On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells,” *Neuroscience Letters*, vol. 314, no. 1-2, pp. 45–48, 2001.

[50] U. Goldbourt and J. H. Medalie, “High density lipoprotein cholesterol and incidence of coronary heart disease—the Israeli ischemic heart disease study,” *American Journal of Epidemiology*, vol. 109, no. 3, pp. 296–308, 1979.

[51] N. E. Miller, D. B. Weinstein, and T. E. Carew, “Interaction between high density and low density lipoproteins during uptake and degradation by cultured human fibroblasts,” *Journal of Clinical Investigation*, vol. 60, no. 1, pp. 78–88, 1977.

[52] D. W. Desmond, J. T. Moroney, M. C. Paik et al., “Frequency and clinical determinants of dementia after ischemic stroke,” *Neurology*, vol. 54, no. 5, pp. 1124–1131, 2000.

[53] J. Zhang, R. E. McKeown, and I. Hajjar, “Serum cholesterol levels are associated with impaired recall memory among older people,” *Age and Ageing*, vol. 34, no. 2, pp. 178–182, 2005.

[54] E. Van Exel, A. J. M. De Craen, J. Gusekloo et al., “Association between high-density lipoprotein and cognitive impairment in the oldest old,” *Annals of Neurology*, vol. 51, no. 6, pp. 716–721, 2002.

[55] A. Merched, Y. Xia, S. Visvikis, J. M. Serot, and G. Siest, “Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer’s disease,” *Neurobiology of Aging*, vol. 21, no. 1, pp. 27–30, 2000.

[56] H. Wolf, A. Hensel, T. Arendt, M. Kivipelto, B. Winblad, and H. J. Gertz, “Serum lipids and hippocampal volume: the link to Alzheimer’s disease?” *Annals of Neurology*, vol. 56, no. 5, pp. 745–748, 2004.

[57] G. W. Cockerill, K. A. Rye, J. R. Gamble, M. A. Vadas, and P. J. Barter, “High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 15, no. 11, pp. 1987–1994, 1995.

[58] G. Zuliani, S. Volpato, A. Blé et al., “High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: the InChianti study,” *Atherosclerosis*, vol. 192, no. 2, pp. 384–390, 2007.

[59] O. F. Olesen and L. Dago, “High density lipoprotein inhibits assembly of amyloid β-peptides into fibrils,” *Biochemical and Biophysical Research Communications*, vol. 270, no. 1, pp. 62–66, 2000.

[60] A. R. Koudinov, N. V. Koudinova, A. Kumar, R. C. Beavis, and J. Ghiso, “Biochemical characterization of Alzheimer’s soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins,” *Biochemical and Biophysical Research Communications*, vol. 223, no. 3, pp. 592–597, 1996.

[61] H. Scharnagl, U. Tisijar, K. Winkler et al., “The βA4 amyloid peptide complexes to and enhances the uptake of β-very low density lipoproteins by the low density lipoprotein receptor-related protein and heparan sulfate proteoglycan pathways,” *Laboratory Investigation*, vol. 79, no. 10, pp. 1271–1286, 1999.

[62] G. M. Cole, W. Beech, S. A. Frautschy, J. Sigel, C. Glasgow, and M. D. Ard, “Lipoprotein effects on Aβ accumulation and degradation by microglia in vitro,” *Journal of Neuroscience Research*, vol. 57, no. 4, pp. 504–520, 1999.

[63] Z. S. Farhangrazi, H. Ying, G. Bu et al., “High density lipoprotein decreases β-amyloid toxicity in cortical cell culture,” *NeuroReport*, vol. 8, no. 5, pp. 1127–1130, 1997.

[64] W. R. Markesbery, “Oxidative stress hypothesis in Alzheimer’s disease,” *Free Radical Biology and Medicine*, vol. 23, no. 1, pp. 134–147, 1997.

[65] G. Perry, A. Nunnomura, K. Hirai et al., “Is oxidative damage the fundamental pathogenic mechanism of Alzheimer’s and other neurodegenerative diseases?” *Free Radical Biology and Medicine*, vol. 33, no. 11, pp. 1475–1479, 2002.

[66] B. I. Van Lenten, M. Navah, D. Shib, A. M. Fogelman, and A. J. Lusis, “The role of high-density lipoproteins in oxidation and inflammation,” *Trends in Cardiovascular Medicine*, vol. 11, no. 3-4, pp. 155–161, 2001.

[67] P. N. Durrington, B. Mackness, and M. I. Mackness, “Paraoxonase and atherosclerosis,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 21, no. 4, pp. 473–480, 2001.

[68] V. Tsimiromadinos, S. A. P. Karabina, A. P. Tambaki et al., “Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 22, no. 2, pp. 306–311, 2002.

[69] J. Goyal, K. Wang, M. Liu, and P. V. Subbaiah, “Novel function of lecithin-cholesterol acyltransferase: hydrolysis of oxidized pol phospholipids generated during lipoprotein oxidation,” *Journal of Biological Chemistry*, vol. 272, no. 26, pp. 16231–16239, 1997.

[70] T. O. Obisean, R. E. Ferrell, A. P. Goldberg, D. A. Phares, T. J. Ellis, and J. M. Hagberg, “APOE genotype affects black-white responses of high-density lipoprotein cholesterol subspecies to aerobic exercise training,” *Metabolism*, vol. 57, no. 12, pp. 1669–1676, 2008.

[71] A. Minagar, P. Shapshak, R. Fujimura, R. Ownby, M. Heyes, and C. Eis dorfer, “The role of macrophase/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis,” *Journal of the Neurological Sciences*, vol. 202, no. 1-2, pp. 13–23, 2002.

[72] P. L. McGeer and E. G. McGeer, “Local neuroinflammation and the progression of Alzheimer’s disease,” *Journal of Neuro-Virology*, vol. 8, no. 6, pp. 529–538, 2002.

[73] R. A. Frank, D. Galasko, H. Hampel et al., “Biological markers for therapeutic trials in Alzheimer’s disease: Proceedings of
the biological markers working group; NIA initiative on neuroimaging in Alzheimer’s disease,” Neurobiology of Aging, vol. 24, no. 4, pp. 521–536, 2003.

[74] P. S. Aisen, “Inflammation and Alzheimer’s disease: mechanisms and therapeutic strategies,” Gerontology, vol. 43, no. 1-2, pp. 143–149, 1997.

[75] P. L. McGeer and E. G. McGeer, “Anti-inflammatory drugs in the fight against Alzheimer’s disease,” Annals of the New York Academy of Sciences, vol. 777, pp. 213–220, 1996.

[76] P. S. Aisen, K. A. Schafer, M. Grundman et al., “Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial,” Journal of the American Medical Association, vol. 289, no. 21, pp. 2819–2826, 2003.

[77] P. S. Aisen, “The potential of anti-inflammatory drugs for the treatment of Alzheimer’s disease,” Lancet Neurology, vol. 1, no. 5, pp. 279–284, 2002.

[78] T. O. Obisesan, C. Leeuwenburgh, T. Phillips et al., “C-reactive protein genotypes affect baseline, but not exercise training-induced changes, in C-reactive protein levels,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 10, pp. 1874–1879, 2004.

[79] H. K. Kuo, C. J. Yen, J. H. Chen, Y. H. Yu, and J. F. Bean, “Association of cardiorespiratory fitness and levels of C-reactive protein: data from the National Health and Nutrition Examination Survey 1999–2002,” International Journal of Cardiology, vol. 114, no. 1, pp. 28–33, 2007.

[80] W. H. Frishman, V. Azer, and D. Sica, “Drug treatment of orthostatic hypotension and vasovagal syncope,” Heart Disease, vol. 5, no. 1, pp. 49–64, 2003.

[81] T. A. Manolio, J. Olson, and W. T. Longstreth, “Hypertension and cognitive function: pathophysiologic effects of hypertension on the brain,” Current Hypertension Reports, vol. 5, no. 3, pp. 255–261, 2003.

[82] E. S. C. Korf, L. R. White, P. Scheltens, and L. J. Launer, “Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia aging study,” Hypertension, vol. 44, no. 1, pp. 29–34, 2004.

[83] T. M. Asikainen, K. Kukkonen-Harjula, and S. Miilunpalo, “Exercise for health for early postmenopausal women: a systematic review of randomised controlled trials,” Sports Medicine, vol. 34, no. 11, pp. 753–778, 2004.

[84] K. J. Stewart, A. C. Bacher, K. L. Turner et al., “Effect of exercise on blood pressure in older persons: a randomized controlled trial,” Archives of Internal Medicine, vol. 165, no. 7, pp. 756–762, 2005.

[85] J. M. Jones, J. J. Park, J. Johnson et al., “Renin-angiotensin system genes and exercise training-induced changes in sodium excretion in African American hypertensives,” Ethnicity and Disease, vol. 16, no. 3, pp. 666–674, 2006.

[86] W. J. Lukiw and N. G. Bazan, “Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex,” Journal of Neuroscience Research, vol. 50, no. 6, pp. 937–945, 1997.

[87] D. J. Perkins and D. A. Kniss, “Tumor necrosis factor-α promotes sustained cyclooxygenase-2 expression: attenuation by dexamethasone and NSAIDs,” Prostaglandins, vol. 54, no. 4, pp. 727–743, 1997.

[88] M. Hül, K. Lieb, and B. L. Fiebich, “Pathways of inflammatory activation in Alzheimer’s disease: potential targets for disease modifying drugs,” Current Medicinal Chemistry, vol. 9, no. 1, pp. 83–88, 2002.

[89] N. G. Kim, H. Lee, E. Son et al., “Hypoxic induction of caspase-11/caspase-1/interleukin-1β in brain microglia,” Molecular Brain Research, vol. 114, no. 2, pp. 107–114, 2003.

[90] D. Praticò, “Alzheimer’s disease and oxygen radicals: new insights,” Biochemical Pharmacology, vol. 63, no. 4, pp. 563–567, 2002.

[91] R. Mielle, H. H. Schopphoff, H. Kugel et al., “Relation between 1H MR spectroscopic imaging and regional cerebral glucose metabolism in Alzheimer’s disease,” International Journal of Neuroscience, vol. 107, no. 3-4, pp. 233–245, 2001.

[92] R. Mielle, R. Schroder, G. R. Fink, J. Kessler, K. Herholz, and W. D. Heiss, “Regional cerebral glucose metabolism and postmortem pathology in Alzheimer’s disease,” Acta Neurologica, vol. 91, no. 2, pp. 174–179, 1996.

[93] G. L. Semenza, F. Agani, N. Iyer et al., “Regulation of cardiovascular development and physiology by hypoxia-inducible factor 1,” Annals of the New York Academy of Sciences, vol. 874, pp. 262–268, 1999.

[94] R. Wang, Y. W. Zhang, X. Zhang et al., “Transcriptional regulation of AP1-1A and increased gamma-secretase cleavage of APP and Notch by HIF-1 and hypoxia,” The FASEB Journal, vol. 20, no. 8, pp. 1275–1277, 2006.

[95] S. Rovio, I. Käränholt, E. L. Helkala et al., “Leisure-time physical activity at midlife and the risk of dementia and Alzheimer’s disease,” Lancet Neurology, vol. 4, no. 11, pp. 705–711, 2005.

[96] L. J. Podewils, E. Guallar, L. H. Kuller et al., “Physical activity, APOE genotype, and dementia risk: findings from the cardiovascular health cognition study,” American Journal of Epidemiology, vol. 161, no. 7, pp. 639–651, 2005.

[97] A. F. Kramer, S. Hahn, N. J. Cohen et al., “Ageing, fitness and neurocognitive function,” Nature, vol. 400, no. 6743, pp. 418–419, 1999.

[98] W. J. Chodzko-Zajko and K. A. Moore, “Physical fitness and cognitive functioning in aging,” Exercise and Sport Sciences Reviews, vol. 22, pp. 195–220, 1994.

[99] P. S. Aisen, “Exercise and Alzheimer’s disease: potential benefits, mechanisms, and perspectives,” Mayo Clinic Proceedings, vol. 86, no. 9, pp. 876–884, 2011.

[100] D. R. Seshadri, M. A. Mintun, A. M. Fagan et al., “Exercise and Alzheimer’s disease biomarkers in cognitively normal older adults,” Journal of the American Geriatrics Society, vol. 59, no. 7, pp. 1108–1117, 2011.
[107] K. I. Erickson, M. W. Voss, R. S. Prakash et al., "Exercise training increases size of hippocampus and improves memory," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 7, pp. 3017–3022, 2011.

[108] V. Antoine and A. S. Rigaud, "Alzheimer’s disease: cardiovascular risk factors must be assessed," Revue de Medecine Interne, vol. 27, no. 1, pp. 21–31, 2006.

[109] R. Ravona- Springer, M. Davidson, and S. Noy, "The role of cardiovascular risk factors in Alzheimer’s disease," CNS Spectrums, vol. 8, no. 11, pp. 824–831, 2003.

[110] T. O. Obisesan, C. Leeuwenburgh, R. E. Ferrell et al., "Cardiovascular risk factors in Alzheimer’s disease: the role of inflammation in the pathogenesis of late-onset Alzheimer’s disease," Brain Research, vol. 101, no. 4, pp. 1237–1242, 2006.

[111] H. Blain, A. Vuillemin, A. Blain, and C. Jeandel, "Preventive effects of physical activity in older adults," Presse Medicale, vol. 29, no. 22, pp. 1240–1248, 2000.

[112] S. Kalmijn, L. J. Launer, R. P. Stolk et al., "A prospective study of arterial stiffness and incident CHD: the Rotterdam Study," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 5, pp. 832–837, 2003.

[113] R. A. Johnson and G. S. Mitchell, "Exercise-induced changes in hippocampal brain-derived neurotrophic factor and neurotrophin-3: effects of rat strain," Brain Research, vol. 983, no. 1–2, pp. 108–114, 2003.

[114] C. H. E. Imray, S. D. Myers, K. T. S. Pattinson et al., "Exercise and the aging brain," Journal of Applied Physiology, vol. 99, no. 2, pp. 699–706, 2005.

[115] S. J. Colcombe, A. F. Kramer, K. I. Erickson et al., "Cardiovascular fitness, cortical plasticity, and aging," Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 3316–3321, 2004.

[116] A. F. Kramer, K. I. Erickson, and S. J. Colcombe, "Exercise, cognition, and the aging brain," Journal of Applied Physiology, vol. 101, no. 4, pp. 1237–1242, 2006.

[117] A. M. Saunders, K. Schmader, J. C. S. Breitner et al., "Apolipoprotein E ε4 allele distributions in late-onset Alzheimer’s disease and in other amyloid-forming diseases," Lancet, vol. 342, no. 8873, pp. 710–711, 1993.

[118] A. M. Saunders, W. J. Strittmatter, D. Schmechel et al., "Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer’s disease," Neurology, vol. 43, no. 8, pp. 1467–1472, 1993.

[119] R. Prior, G. Wihl, and B. Urmonet, "Apolipoprotein E, smooth muscle cells and the pathogenesis of cerebral amyloid angiopathy: the potential role of impaired cerebrovascular Aβ clearance," Annals of the New York Academy of Sciences, vol. 903, pp. 180–186, 2000.

[120] J. Davignon, R. E. Gregg, and C. F. Sing, "Apolipoprotein E polymorphism and atherosclerosis," Arteriosclerosis, vol. 8, no. 1, pp. 1–21, 1988.

[121] J. Davignon and G. Roederer, "Apolipoprotein E phenotype, hyperlipidemia and atherosclerosis," Union Medica de Canada, vol. 117, no. 1, pp. 56–61, 1988.

[122] P. Zimethbaum, W. H. Frishman, Wee Lock Ooi et al., "Plasma lipids and lipoproteins and the incidence of cardiovascular disease in the very elderly: the Bronx aging study," Arteriosclerosis and Thrombosis, vol. 12, no. 4, pp. 416–423, 1992.

[123] R. Benfante and D. Reed, "Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly?" Journal of the American Medical Association, vol. 263, no. 3, pp. 393–396, 1990.

[124] B. Sepehrnia, M. I. Kamboh, L. L. Adams-Campbell et al., "Genetic studies of human apolipoproteins. XI. The effect of the apolipoprotein C-II polymorphism on lipoprotein levels in Nigerian blacks," Journal of Lipid Research, vol. 30, no. 9, pp. 1349–1355, 1989.

[125] M. I. Kamboh, C. E. Aston, R. E. Ferrell, and R. F. Hamman, "Impact of apolipoprotein E polymorphism in determining interindividual variation in total cholesterol and low density lipoprotein cholesterol in Hispanics and non-Hispanic whites," Arteriosclerosis, vol. 98, no. 2, pp. 201–211, 1993.

[126] R. Zoratti, "A review on ethnic differences in plasma triglycerides and high-density-lipoprotein cholesterol: is the lipid pattern the key factor for the low coronary heart disease rate in people of African origin?" European Journal of Epidemiology, vol. 14, no. 1, pp. 9–21, 1998.

[127] L. O. Watkins, J. D. Neaton, and L. H. Kuller, "Racial differences in high-density lipoprotein cholesterol and coronary heart disease incidence in the usual-care group of the multiple risk factor intervention trial," American Journal of Cardiology, vol. 57, no. 8, pp. 538–545, 1986.

[128] J. Gorski, "Muscle triglyceride metabolism during exercise," Canadian Journal of Physiology and Pharmacology, vol. 70, no. 1, pp. 123–131, 1992.

[129] P. D. Thompson, E. M. Cullinane, S. P. Sady, M. M. Flynn, C. B. Chenevert, and P. N. Herbert, "High density lipoprotein metabolism in endurance athletes and sedentary men," Circulation, vol. 84, no. 1, pp. 140–152, 1991.

[130] J. A. Blumenthal, K. Matthews, M. Fredrikson et al., "Effects of exercise training on cardiovascular function and plasma lipid, lipoprotein, and apolipoprotein concentrations in premenopausal and postmenopausal women," Arteriosclerosis and Thrombosis, vol. 11, no. 4, pp. 912–917, 1991.

[131] J. A. Blumenthal, C. F. Emery, D. J. Madden et al., "Effects of exercise training on cardiorespiratory function in men and women older than 60 years of age," American Journal of Cardiology, vol. 67, no. 7, pp. 633–639, 1991.

[132] T. D. Agurs-Collins, S. K. Kumanyika, T. R. Ten Have, and L. L. Adams-Campbell, "A randomized controlled trial of weight reduction and exercise for diabetes management in older African-American subjects," Diabetes Care, vol. 20, no. 10, pp. 1503–1511, 1997.

[133] C. J. Crespo, S. J. Keteyian, G. W. Heath, and C. T. Sembros, "Leisure-time physical activity among US adults: results from the third national health and nutrition examination survey," Archives of Internal Medicine, vol. 156, no. 1, pp. 93–98, 1996.

[134] H. N. Williford, D. L. Blessing, W. J. Duyet al., "Exercise training in black adolescents: changes in blood lipids and VO2max," Ethnicity and Disease, vol. 6, no. 3–4, pp. 279–285, 1996.

[135] J. T. Soler, A. R. Folsom, L. H. Kushi, R. J. Prineas, and U. S. Seal, "Association of body fat distribution with plasma lipids, lipoproteins, apolipoproteins AI and B in postmenopausal women," Journal of the American Medical Association, vol. 263, no. 3, pp. 1075–1081, 1988.

[136] N. J. Doshi, R. S. Hurley, M. E. Garrison et al., "Effectiveness of a nutrition education and physical fitness training program in lowering lipid levels in the black elderly," Journal of Nutrition for the Elderly, vol. 13, no. 3, pp. 23–33, 1994.

[137] P. B. Sparling, T. D. Noakes, K. S. Steyn et al., "Level of physical activity and CHD risk factors in black South African men," Medicine and Science in Sports and Exercise, vol. 26, no. 7, pp. 896–902, 1994.

[138] A. F. Kramer, S. J. Colcombe, E. McAuley et al., "Enhancing brain and cognitive function of older adults through fitness training," Journal of Molecular Neuroscience, vol. 20, no. 3, pp. 213–221, 2003.